The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | TROP2 protein and RNA expression in NSCLC tissue
Jessy Deshane, PhD, University of Alabama at Birmingham, Birmingham, AL, explores findings from a paired spatial transcriptomic and proteomic mapping study examining TROP2 expression in non-small cell lung cancer (NSCLC) tissue. TROP2 protein and RNA were found to be discordant, and TROP2-high tumors were found to have low immune checkpoint expression, which could be used to inform use of TROP2-targeting antibody-drug conjugates. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
